<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769586</url>
  </required_header>
  <id_info>
    <org_study_id>0003</org_study_id>
    <nct_id>NCT01769586</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Diphenhydramine Versus Continued Midazolam in &quot;Difficult-to-sedate&quot; Patients Undergoing Colonoscopy</brief_title>
  <official_title>Randomized Trial of Diphenhydramine Versus Continued Midazolam in &quot;Difficult-to-sedate&quot; Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Connecticut Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Connecticut Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who are undergoing colonoscopy and are not adequately sedated after initial standard
      sedation with midazolam 5 mg and fentanyl 100 mcg will be randomly assigned to receive
      diphenhydramine vs. continued midazolam, and their level of sedation will be assessed. Our
      hypothesis is that diphenhydramine will provide better sedation than continued administration
      of midazolam during colonoscopy in patients not achieving adequate sedation with standard
      doses of midazolam plus fentanyl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are undergoing colonoscopy and are not adequately sedated after initial standard
      sedation with midazolam 5 mg and fentanyl 100 mcg will be randomly assigned to receive
      diphenhydramine (up to 3 incremental doses of 25 mcg each) vs. continued midazolam (up to 3
      incremental doses of 1.5 mg each). the level of sedation will be assessed using the MOAA/S
      scale 2-3 minutes after each administration to determine if they are sufficiently sedated to
      begin colonoscopy. The patient, the healthcare team involved in performing the endoscopy, and
      the investigator assessing sedation will be blinded to the therapy. Our hypothesis is that
      diphenhydramine will provide better sedation than continued administration of midazolam
      during colonoscopy in patients not achieving adequate sedation with standard doses of
      midazolam plus fentanyl.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Achieve Adequate Sedation to Allow Colonoscopy (Defined as MOAA/S ≤3)</measure>
    <time_frame>Approximately 10 minutes or less</time_frame>
    <description>Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale. This scale ranges from 0 to 5, where 0 denotes general anesthesia, in which the patient has no response to painful stimuli, and 5 denotes a level of minimal sedation in which the patient is fully awake.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Sedation</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increments of 25 mcg to maximum of 3 times (total 75 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 mg increments up to 3 times (maximum 4.5 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <arm_group_label>Diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years-old who are undergoing elective colonoscopy with conscious sedation

        Exclusion Criteria:

          -  allergy or prior adverse reactions to diphenhydramine

          -  medical contraindications to use of diphenhydramine (e.g. closed angle glaucoma)

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loren Laine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <results_first_submitted>July 11, 2016</results_first_submitted>
  <results_first_submitted_qc>August 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2016</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Diphenhydramine</keyword>
  <keyword>Midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diphenhydramine</title>
          <description>Increments of 25 mcg to maximum of 3 times (total 75 mcg)
Diphenhydramine</description>
        </group>
        <group group_id="P2">
          <title>Midazolam</title>
          <description>1.5 mg increments up to 3 times (maximum 4.5 mg)
Midazolam</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diphenhydramine</title>
          <description>Increments of 25 mcg to maximum of 3 times (total 75 mcg)
Diphenhydramine</description>
        </group>
        <group group_id="B2">
          <title>Midazolam</title>
          <description>1.5 mg increments up to 3 times (maximum 4.5 mg)
Midazolam</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="28" upper_limit="76"/>
                    <measurement group_id="B2" value="61" lower_limit="27" upper_limit="76"/>
                    <measurement group_id="B3" value="60" lower_limit="27" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Achieve Adequate Sedation to Allow Colonoscopy (Defined as MOAA/S ≤3)</title>
        <description>Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) scale. This scale ranges from 0 to 5, where 0 denotes general anesthesia, in which the patient has no response to painful stimuli, and 5 denotes a level of minimal sedation in which the patient is fully awake.</description>
        <time_frame>Approximately 10 minutes or less</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine</title>
            <description>Increments of 25 mcg to maximum of 3 times (total 75 mcg)
Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>1.5 mg increments up to 3 times (maximum 4.5 mg)
Midazolam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieve Adequate Sedation to Allow Colonoscopy (Defined as MOAA/S ≤3)</title>
          <description>Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) scale. This scale ranges from 0 to 5, where 0 denotes general anesthesia, in which the patient has no response to painful stimuli, and 5 denotes a level of minimal sedation in which the patient is fully awake.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.24</ci_lower_limit>
            <ci_upper_limit>.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diphenhydramine</title>
          <description>Increments of 25 mcg to maximum of 3 times (total 75 mcg)
Diphenhydramine</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>1.5 mg increments up to 3 times (maximum 4.5 mg)
Midazolam</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Desaturation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Loren Laine</name_or_title>
      <organization>VA Connecticut Healthcare System</organization>
      <phone>203-932-5711</phone>
      <email>loren.laine@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

